{"filing":{"accession_number":"0001104659-26-116876","cik":"0001267565","ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-15","primary_document":"tm2627827d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465926116876/tm2627827d1_8k.htm"},"events":[{"id":36059,"run_id":33244,"accession_number":"0001104659-26-116876","anchor_item_number":"1.02","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses termination of a material license agreement (Grünenthal License) and related consent agreement following a settlement of patent litigation. The Company paid $17 million to resolve all disputes, obtained assignment of patents related to Nucynta Products, and eliminated all future royalty obligations. While Item 1.02 addresses termination of material agreements, the substance here—settlement of litigation, patent assignment, and elimination of ongoing royalty obligations—constitutes a material restructuring of the Company's rights and obligations regarding a key product line (Nucynta), warranting classification as a material transaction or settlement activity rather than a routine agreement termination.","company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40334,"accession_number":"0001104659-26-116876","item_number":"1.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of a material license agreement (Grünenthal License) and related consent agreement following a settlement of patent litigation. The Company paid $17 million to resolve all disputes, obtained assignment of patents related to Nucynta Products, and eliminated all future royalty obligations. While Item 1.02 addresses termination of material agreements, the substance here—settlement of litigation, patent assignment, and elimination of ongoing royalty obligations—constitutes a material restructuring of the Company's rights and obligations regarding a key product line (Nucynta), warranting classification as a material transaction or settlement activity rather than a routine agreement termination.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:07:05.456134+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40334,"accession_number":"0001104659-26-116876","item_number":"1.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of a material license agreement (Grünenthal License) and related consent agreement following a settlement of patent litigation. The Company paid $17 million to resolve all disputes, obtained assignment of patents related to Nucynta Products, and eliminated all future royalty obligations. While Item 1.02 addresses termination of material agreements, the substance here—settlement of litigation, patent assignment, and elimination of ongoing royalty obligations—constitutes a material restructuring of the Company's rights and obligations regarding a key product line (Nucynta), warranting classification as a material transaction or settlement activity rather than a routine agreement termination.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:07:05.456134+00:00","company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","filing_date":"2026-10-19"}]}